

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
13 December 2001 (13.12.2001)


PCT

(10) International Publication Number
WO 01/94351 A1

- (51) International Patent Classification⁷: **C07D 487/04**, 471/04, 487/22, A61K 31/47, 31/50, 31/505 // (C07D 487/04, 239:00, 209:00) (C07D 471/04, 221:00, 209:00)
- (74) Agents: **SILVERMAN, Ian**; Vertex Pharmaceuticals Inc., 130 Waverly Street, Cambridge, MA 02139-4242 et al. (US).
- (21) International Application Number: **PCT/US01/18243**
- (22) International Filing Date: **5 June 2001 (05.06.2001)**
- (25) Filing Language: **English**
- (26) Publication Language: **English**
- (30) Priority Data:
60/209,929 **7 June 2000 (07.06.2000)** **US**
- (71) Applicant (for all designated States except US): **VERTEX PHARMACEUTICALS INCORPORATED** [US/US]; Patent Department, 130 Waverly Street, Cambridge, MA 02139-4242 (US).
- (81) Designated States (national): **AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW.**
- (84) Designated States (regional): **ARIPO** patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), **Eurasian** patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), **European** patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR), **OAPI** patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).
- (72) Inventors; and
- (75) Inventors/Applicants (for US only): **CHARRIER, Jean-Damien** [FR/GB]; Vertex Pharmaceuticals Inc., Cottage Wing, Station Road, Southam, Bishops Itchington, Oxfordshire CV47 2QB (GB). **BRENCHLEY, Guy** [GB/GB]; Vertex Pharmaceuticals Ltd., 12 Boucher Close, Grove Wantage, Oxon, Oxfordshire OX12 ONE (GB).
- Published:
— with international search report
- For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

WO 01/94351 A1

(54) Title: **CASPASE INHIBITORS AND USES THEREOF**



more halogen, C₁₋₄ alkyl, or C₁₋₄ alkoxy. The compounds are useful for treating caspase-mediated diseases.

(57) Abstract: This invention provides novel caspase inhibitors of formula I wherein R¹ is hydrogen, CHN₂, R, or -CH₂Y; R is an aliphatic group, an aryl group, an alkyl group, a heterocyclyl group, or a heterocyclylalkyl group; Y is an electronegative leaving group; R² is CO₂H, CH₂CO₂H, or esters, amides or isosteres thereof; X₂-X₁ is N(R³)-C(R³), C(R³)₂-C(R³), C(R³)₂-N, N=C, C(R³)=C, C(=O)-N, or C(=O)-C(R³), each R³ is independently selected from hydrogen or C₁₋₆ aliphatic; Ring C is a fused aryl ring; n is 0, 1 or 2; and each methylene carbon in Ring A is optionally and independently substituted by =O, or one or

BEST AVAILABLE COPY

CASPASE INHIBITORS AND USES THEREOF

Cross-Reference to Related Applications

This application claims priority to US Provisional Patent Application 60/209,929 filed June 7, 2000, the contents of which are incorporated herein by reference.

Field of the Invention

This invention is in the field of medicinal chemistry and relates to novel compounds, and pharmaceutical compositions thereof, that inhibit caspases that mediate cell apoptosis and inflammation.

5 The invention also relates to methods of using the compounds and pharmaceutical compositions of this invention to treat diseases where caspase activity is implicated.

Background of the Invention

10 Apoptosis, or programmed cell death, is a principal mechanism by which organisms eliminate unwanted cells. The deregulation of apoptosis, either excessive apoptosis or the failure to undergo it, has been implicated in a number of diseases such as cancer, acute

15 inflammatory and autoimmune disorders, ischemic diseases and certain neurodegenerative disorders (see generally *Science*, 1998, **281**, 1283-1312; Ellis et al., *Ann. Rev. Cell. Biol.*, 1991, **7**, 663).

Caspases are a family of cysteine protease

20 enzymes that are key mediators in the signaling pathways for apoptosis and cell disassembly (Thornberry, *Chem. Biol.*, 1998, **5**, R97-R103). These signaling pathways vary

-2-

depending on cell type and stimulus, but all apoptosis pathways appear to converge at a common effector pathway leading to proteolysis of key proteins. Caspases are involved in both the effector phase of the signaling pathway and further upstream at its initiation. The upstream caspases involved in initiation events become activated and in turn activate other caspases that are involved in the later phases of apoptosis.

Caspase-1, the first identified caspase, is also known as interleukin converting enzyme or "ICE." Caspase-1 converts precursor interleukin-1 β ("pIL-1 β ") to the pro-inflammatory active form by specific cleavage of pIL-1 β between Asp-116 and Ala-117. Besides caspase-1 there are also eleven other known human caspases, all of which cleave specifically at aspartyl residues. They are also observed to have stringent requirements for at least four amino acid residues on the N-terminal side of the cleavage site.

The caspases have been classified into three groups depending on the amino acid sequence that is preferred or primarily recognized. The group of caspases, which includes caspases 1, 4, and 5, has been shown to prefer hydrophobic aromatic amino acids at position 4 on the N-terminal side of the cleavage site. Another group which includes caspases 2, 3 and 7, recognize aspartyl residues at both positions 1 and 4 on the N-terminal side of the cleavage site, and preferably a sequence of Asp-Glu-X-Asp. A third group, which includes caspases 6, 8, 9 and 10, tolerate many amino acids in the primary recognition sequence, but seem to prefer residues with branched, aliphatic side chains such as valine and leucine at position 4.

-3-

The caspases have also been grouped according to their perceived function. The first subfamily consists of caspases-1 (ICE), 4, and 5. These caspases have been shown to be involved in pro-inflammatory cytokine processing and therefore play an important role in inflammation. Caspase-1, the most studied enzyme of this class, activates the IL-1 β precursor by proteolytic cleavage. This enzyme therefore plays a key role in the inflammatory response. Caspase-1 is also involved in the processing of interferon gamma inducing factor (IGIF or IL-18) which stimulates the production of interferon gamma, a key immunoregulator that modulates antigen presentation, T-cell activation and cell adhesion.

The remaining caspases make up the second and third subfamilies. These enzymes are of central importance in the intracellular signaling pathways leading to apoptosis. One subfamily consists of the enzymes involved in initiating events in the apoptotic pathway, including transduction of signals from the plasma membrane. Members of this subfamily include caspases-2, 8, 9 and 10. The other subfamily, consisting of the effector caspases 3, 6 and 7, are involved in the final downstream cleavage events that result in the systematic breakdown and death of the cell by apoptosis. Caspases involved in the upstream signal transduction activate the downstream caspases, which then disable DNA repair mechanisms, fragment DNA, dismantle the cell cytoskeleton and finally fragment the cell.

A four amino acid sequence primarily recognized by the caspases has been determined for enzyme substrates. Talanian et al., *J. Biol. Chem.* **272**, 9677-9682, (1997); Thornberry et al., *J. Biol. Chem.* **272**,

-4-

17907-17911, (1997). Knowledge of the four amino acid sequence primarily recognized by the caspases has been used to design caspase inhibitors. Reversible tetrapeptide inhibitors have been prepared having the structure $\text{CH}_3\text{CO}-[\text{P4}]-[\text{P3}]-[\text{P2}]-\text{CH}(\text{R})\text{CH}_2\text{CO}_2\text{H}$ where P2 to P4 represent an optimal amino acid recognition sequence and R is an aldehyde, nitrile or ketone capable of binding to the caspase cysteine sulfhydryl. Rano and Thornberry, *Chem. Biol.* **4**, 149-155 (1997); Mjalli, et al., *Bioorg. Med. Chem. Lett.* **3**, 2689-2692 (1993); Nicholson et al., *Nature* **376**, 37-43 (1995). Irreversible inhibitors based on the analogous tetrapeptide recognition sequence have been prepared where R is an acyloxymethylketone - $\text{COCH}_2\text{OCOR}'$. R' is exemplified by an optionally substituted phenyl such as 2,6-dichlorobenzoyloxy and where R is COCH_2X where X is a leaving group such as F or Cl. Thornberry et al., *Biochemistry* **33**, 3934 (1994); Dolle et al., *J Med. Chem.* **37**, 563-564 (1994).

The utility of caspase inhibitors to treat a variety of mammalian disease states associated with an increase in cellular apoptosis has been demonstrated using peptidic caspase inhibitors. For example, in rodent models, caspase inhibitors have been shown to reduce infarct size and inhibit cardiomyocyte apoptosis after myocardial infarction, to reduce lesion volume and neurological deficit resulting from stroke, to reduce post-traumatic apoptosis and neurological deficit in traumatic brain injury, to be effective in treating fulminant liver destruction, and to improve survival after endotoxic shock. Yaoita et al., *Circulation*, **97**, 276 (1998); Endres et al., *J Cerebral Blood Flow and Metabolism*, **18**, 238, (1998); Cheng et al., *J. Clin.*


-5-

Invest., **101**, 1992 (1998); Yakovlev et al., *J. Neuroscience*, **17**, 7415 (1997); Rodriguez et al., *J. Exp. Med.*, **184**, 2067 (1996); Grobmyer et al., *Mol. Med.*, **5**, 585 (1999).

5 In general, the peptidic inhibitors described above are very potent against some of the caspase enzymes. However, this potency has not always been reflected in cellular models of apoptosis. In addition peptide inhibitors are typically characterized by
10 undesirable pharmacological properties such as poor oral absorption, poor stability and rapid metabolism. Plattner and Norbeck, in *Drug Discovery Technologies*, Clark and Moos, Eds. (Ellis Horwood, Chichester, England, 1990).

15 Recognizing the need to improve the pharmacological properties of the peptidic caspase inhibitors, peptidomimetic and non-natural amino acid peptide inhibitors have been reported.


 EP618223 discloses peptides inhibiting
20 interleukin 1-beta release of the formula:



 wherein R is a hydrogen, an amino or hydroxy protecting group or optionally ring substituted benzyloxy, A₃ is -CH₂-X₁-CO-Y₁; -CH₂-O-Y₂; or -CH₂-S-Y₃; wherein X₁ is O or S
25 and Y₁, Y₂, and Y₃ are as defined in the specification.


 WO 97/22619 discloses ICE inhibitors which contain a piperazic acid unit:

-6-



wherein R_1 is CO_2H or a bioisosteric replacement of CO_2H ;
 R_2 is H, alkyl, aryl, heteroaryl, or CH_2Y ; R_3 is H, R,
 COOR , $\text{CON}(\text{R})_2$, SO_2R , SO_2NHR , COCH_2OR , COCOR , COCOOR or
 5 $\text{COCON}(\text{R})_2$; Y is OR, SR, or $-\text{OC}=\text{O}(\text{R})$; and R is H, aromatic
 or alkyl group.


WO 9816502 discloses ICE inhibitors which
 contain a proline unit:



10

wherein R_1 is alkyl or $\text{N}(\text{R}_3)_2$; R_2 is H, or OCH_2Aryl ; and
 R_3 is selected from various groups.

Dolle et al. (*J. Med. Chem.* **37**, 563, (1994))
 report ICE inhibitors which contain a pipecolic acid
 15 unit:




While a number of caspase inhibitors have been
 reported, it is not clear whether they possess the
 appropriate pharmacological properties to be
 20 therapeutically useful. Therefore, there is a continued
 need for small molecule caspase inhibitors that are
 potent, stable, and penetrate membranes to provide
 effective inhibition of apoptosis *in vivo*. Such
 compounds would be extremely useful in treating the

-7-

aforementioned diseases where caspase enzymes play a role.

Summary of the Invention

It has now been found that compounds of this invention and pharmaceutical compositions thereof are effective as inhibitors of caspases and cellular apoptosis. These compounds have the general formula I:



I

wherein:

R^1 is hydrogen, CHN_2 , R, or $-CH_2Y$;

R is an aliphatic group, an aryl group, an aralkyl group, a carbocyclyl group, a carbocyclylalkyl group, a heterocyclyl group, or a heterocyclylalkyl group;

Y is an electronegative leaving group;

R^2 is CO_2H , CH_2CO_2H , or esters, amides or isosteres thereof;

X_2-X_1 is $N(R^3)-C(R^3)$, $C(R^3)_2-C(R^3)$, $C(R^3)_2-N$, $N=C$, $C(R^3)=C$, $C(=O)-N$, or $C(=O)-C(R^3)$;

each R^3 is independently selected from hydrogen or C_{1-6} alkyl,

Ring C is a fused aryl ring;

n is 0, 1 or 2; and

any methylene position in Ring A is optionally and independently substituted by $=O$, or one or two groups selected from halogen, C_{1-4} alkyl, or C_{1-4} alkoxy.


The compounds of this invention have potent inhibition properties across a range of caspase targets

-8-

with good efficacy in cellular models of apoptosis, and they are useful for treating caspase-mediated diseases such as those described below.

5 Detailed Description of the Invention

This invention provides novel compounds, and pharmaceutically acceptable derivatives thereof, that are useful as caspase inhibitors. The invention also provides methods for using the compounds to inhibit
 10 caspase activity and to treat caspase-mediated disease states in mammals. These compounds have the general formula I:



I

15

wherein:

R^1 is hydrogen, CHN_2 , R, or $-CH_2Y$;

R is an aliphatic group, an aryl group, an aralkyl group, a heterocyclic group, or a heterocyclalkyl group;

20 Y is an electronegative leaving group;

R^2 is CO_2H , CH_2CO_2H , or esters, amides or isosteres thereof;

X_2-X_1 is $N(R^3)-C(R^3)$, $C(R^3)_2-C(R^3)$, $C(R^3)_2-N$, $N=C$, $C(R^3)=N$, $C(R^3)=C$, $C(=O)-N$, or $C(=O)-C(R^3)$;

25 each R^3 is independently selected from hydrogen or a C_{1-6} aliphatic group,

Ring C is a fused aryl ring;

n is 0, 1 or 2; and

-9-

each methylene carbon in Ring A is optionally and independently substituted by =O, or by one or more halogen, C₁₋₄ alkyl, or C₁₋₄ alkoxy.

As used herein, the following definitions shall
5 apply unless otherwise indicated:

The term "aliphatic" as used herein means straight chained or branched C₁-C₁₂ hydrocarbons which are completely saturated or which contain one or more units of unsaturation. Aliphatic groups include substituted or
10 unsubstituted linear, branched or cyclic alkyl, alkenyl, or alkynyl groups and hybrids thereof such as (cycloalkyl)alkyl, (cycloalkenyl)alkyl or (cycloalkyl)alkenyl. The term "alkyl" used alone or as part of a group or larger moiety refers to both straight
15 and branched chains containing one to twelve carbon atoms. The term "halogen" means F, Cl, Br, or I.

The term "aryl" refers to monocyclic or polycyclic aromatic groups, and monocyclic or polycyclic heteroaromatic groups containing one or more heteroatoms,
20 having five to fourteen atoms. Such groups include, but are not restricted to phenyl, naphthyl, anthryl, furanyl, thienyl, pyrrolyl, oxazolyl, thiazolyl, imidazolyl, pyrazolyl, isoxazolyl, isothiazolyl, oxadiazolyl, triazolyl, thiadiazolyl, pyridinyl, pyridazinyl,
25 pyrimidinyl, pyrazinyl, triazinyl, indolizinyl, indolyl, isoindolyl, indolinyl, benzofuranyl, benzothiophenyl, indazolyl, benzimidazolyl, benzthiazolyl, purinyl, quinolizinyl, quinolinyl, isoquinolinyl, cinnolinyl, phthalazinyl, quinazolinyl, quinoxalinyl, 1,8-
30 naphthyridinyl, pteridinyl, carbazolyl, acridinyl, phenazinyl, phenothiazinyl, phenoxazinyl,

-10-

tetrahydrofuranyl, phthalimidinyl, tetrazolyl, and chromanyl.

The term "heterocyclic group" refers to saturated and unsaturated monocyclic or polycyclic ring systems containing one or more heteroatoms and a ring size of three to eight. Such groups include, but are not restricted to aziranyl, oxiranyl, azetidiny, tetrahydrofuranyl, pyrrolinyl, pyrrolidinyl, dioxolanyl, imidazolinyl, imidazolidinyl, pyrazolinyl, pyrazolidinyl, pyranyl, piperidinyl, dioxanyl, morpholinyl, dithianyl, thiomorpholinyl, piperazinyl, trithianyl, quinuclidinyl, oxepanyl, and thiepanyl.

The term "carbocyclic group" refers to saturated monocyclic or polycyclic carbon ring systems which may be fused to aryl or heterocyclic groups. Examples could include cyclohexyl, cyclopentyl, cyclobutyl, cyclopropyl, indanyl, tetrahydronaphthyl and the like.

An aliphatic, alkyl, aryl, a heterocyclic, or a carbocyclic group may contain one or more substituents. Examples of suitable substituents include a halogen, -R, -OR, -OH, -SH, -SR, protected OH (such as acyloxy), phenyl (Ph), substituted Ph, -OPh, substituted -OPh, -NO₂, -CN, -NH₂, -NHR, -N(R)₂, -NHCOR, -NHCONHR, -NHCON(R)₂, -NRCOR, -NHCO₂R, -CO₂R, -CO₂H, -COR, -CONHR, -CON(R)₂, -S(O)₂R, -SONH₂, -S(O)R, -SO₂NHR, -NHS(O)₂R, =O, =S, =NNHR, =NNR₂, =N-OR, =NNHCOR, =NNHCO₂R, =NNHSO₂R, or =NR where R is an aliphatic group or a substituted aliphatic group.

A substitutable nitrogen on a heterocyclic ring may be optionally substituted. Suitable substituents on

-11-

the nitrogen include R, COR, S(O)₂R, and CO₂R, where R is an aliphatic group or a substituted aliphatic group.

Nitrogen and sulfur may be in their oxidized form, and nitrogen may be in a quaternized form.

5 The term "electronegative leaving group" has the definition known to those skilled in the art (see March, Advanced Organic Chemistry, 4th Edition, John Wiley & Sons, 1992). Examples of electronegative leaving groups include halogens such as F, Cl, Br, I, aryl- and
10 alkylsulfonyloxy groups, trifluoromethanesulfonyloxy, OR, SR, -OC=O(R), -OPO(R³)(R⁴), where R is an aliphatic group, an aryl group, an aralkyl group, a carbocyclic group, an alkyl carbocyclic group, a heterocyclic group, or an alkyl heterocyclic group; and R³ and R⁴ are independently
15 selected from R or OR.


When the R² group is in the form of an ester or amide, the present compounds undergo metabolic cleavage to the corresponding carboxylic acids, which are the active caspase inhibitors. Because they undergo
20 metabolic cleavage, the precise nature of the ester or amide group is not critical to the working of this invention. The structure of the R² group may range from the relatively simple diethyl amide to a steroidal ester. Examples of esters of R² carboxylic acids include, but are
25 not limited to, C₁₋₁₂ aliphatic, such as C₁₋₆ alkyl or C₃₋₁₀ cycloalkyl, aryl, such as phenyl, aralkyl, such as benzyl or phenethyl, heterocyclyl or heterocyclylalkyl. Examples of suitable R² heterocyclyl rings include, but are not limited to, 5-6 membered heterocyclic rings
30 having one or two heteroatoms such as piperidinyl, piperazinyl, or morpholinyl.

-12-

Amides of R^2 carboxylic acids may be primary, secondary or tertiary. Suitable substituents on the amide nitrogen include, but are not limited to, one or more groups independently selected from the aliphatic, aryl, aralkyl, heterocyclyl or heterocyclylalkyl groups described above for the R^2 ester alcohol. Likewise, other prodrugs are included within the scope of this invention. See Bradley D. Anderson, "Prodrugs for Improved CNS Delivery" in Advanced Drug Delivery Reviews (1996), **19**, 171-202.

Isosteres or bioisosteres of R^2 carboxylic acids, esters and amides result from the exchange of an atom or group of atoms to create a new compound with similar biological properties to the parent carboxylic acid or ester. The bioisosteric replacement may be physicochemically or topologically based. An example of an isosteric replacement for a carboxylic acid is $\text{CONHSO}_2(\text{alkyl})$ such as CONHSO_2Me .

Compounds of this invention where R^2 is CO_2H or $\text{CH}_2\text{CO}_2\text{H}$, γ -ketoacids or δ -ketoacids respectively, may exist in solution as either the open form 1 or the cyclized hemiketal form 2 ($y=1$ for γ -ketoacids, $y=2$ for δ -ketoacids). The representation herein of either isomeric form is meant to include the other.



-13-

Likewise it will be apparent to one skilled in the art that certain compounds of this invention may exist in tautomeric forms or hydrated forms, all such forms of the compounds being within the scope of the invention. Unless otherwise stated, structures depicted herein are also meant to include all stereochemical forms of the structure; i.e., the R and S configurations for each asymmetric center. Therefore, single stereochemical isomers as well as enantiomeric and diastereomeric mixtures of the present compounds are within the scope of the invention. Unless otherwise stated, structures depicted herein are also meant to include compounds that differ only in the presence of one or more isotopically enriched atoms. For example, compounds having the present structures except for the replacement of a hydrogen by a deuterium or tritium, or the replacement of a carbon by a ^{13}C - or ^{14}C -enriched carbon are within the scope of this invention.

The compounds of this invention have inhibition properties across a range of caspase targets with good efficacy in cellular models of apoptosis. In addition, these compounds are expected to have good cell penetration and pharmacokinetic properties and, as a consequence of their potency, have good efficacy against diseases where caspases are implicated.

Ring C is preferably a fused five- or six-membered aryl ring having zero to two ring heteroatoms selected from oxygen, sulfur or nitrogen. More preferably Ring C is a fused six-membered aryl ring such as benzene or a ring where the atom adjacent to the Ring B/Ring C ring junction proximal to the Ring B carbonyl is an unsubstituted carbon. Ring C may be substituted or

-14-

unsubstituted. Suitable Ring C substituents include halogen, -R, -OR, -OH, -SH, -SR, protected OH (such as acyloxy), phenyl (Ph), substituted Ph, -OPh, substituted -OPh, -NO₂, -CN, -NH₂, -NHR, -N(R)₂, -NHCOR, -NHCONHR, 5 -NHCON(R)₂, -NRCOR, -NHCO₂R, -CO₂R, -CO₂H, -COR, -CONHR, -CON(R)₂, -S(O)₂R, -SONH₂, -S(O)R, -SO₂NHR, -NHS(O)₂R, =O, =S, =NNHR, =NNR₂, =N-OR, =NNHCOR, =NNHCO₂R, =NNHSO₂R, or =NR where R is an aliphatic group or a substituted aliphatic group.

10 Preferred compounds of this invention are compounds of formula I that have one or more of the following features, and more preferably all of the following features:

- (a) R¹ is -CH₂Y wherein Y is a halogen, OR, SR, or 15 -OC=O(R), wherein R is an aryl group or heterocyclic group;
- (b) R² is CO₂H or esters, amides or isosteres thereof;
- (c) X₂-X₁ is N=C, C(R³)=C, or C(=O)-N;
- 20 (d) Ring C is a fused five or six-membered aromatic ring having zero to two heteroatoms; and/or
- (e) n is 0 or 1,

wherein R³ is as described above. Preferably, R³ is a C₁₋₆ alkyl group.

25 Most preferred compounds of this invention are compounds of formula I that have the following features:


- (a) R¹ is -CH₂Y wherein Y is F;
- (b) R² is CO₂H or an ester thereof;
- (c) X₂-X₁ is N=C, CH=C, or C(=O)-N;
- 30 (d) Ring C is a benzene or pyrazine ring; and
- (e) n is 0 or 1.

-15-


Representative tricyclic ring systems of formula I include, but are not limited to, those provided in Table 1. For illustrative purposes, Ring C is shown as a benzo-fused ring, and not all of the possible R³ substituents are shown. Table 2 that follows shows specific representative examples of formula I compounds.

Table 1. Examples of Tricyclic Systems of Formula I where Ring C is a benzo-fused ring














10



15




-16-

**j****k****l****m****n****o****p****q****r****s****t****u****v**

-17-

Table 2. Examples of Formula I compounds




| Example | R ¹ | R ² | Ring C | n | X ₁ | X ₂ |
|---------|-------------------|-------------------|----------|---|----------------|----------------|
| 1 | CH ₂ F | CO ₂ H | benzo | 0 | C | N |
| 2 | CH ₂ F | CO ₂ H | benzo | 1 | C | N |
| 3 | CH ₂ F | CO ₂ H | benzo | 0 | C | C-H |
| 4 | CH ₂ F | CO ₂ H | benzo | 1 | C | C-H |
| 5 | CH ₂ F | CO ₂ H | benzo | 1 | N | C=O |
| 6 | CH ₂ F | CO ₂ H | pyrazino | 1 | N | C=O |

5

The compounds of this invention may be prepared in general by methods known to those skilled in the art for analogous compounds, as illustrated by the general Scheme I below and by the preparative examples that follow.

10

-18-

Scheme I

Reagents: (a) TFA or KOH/MeOH; (b) EDC/DMAP/HOBt; (c)
 5 Dess-Martin periodinane; (d) TFA/DCM


Tricyclic ring system **1** is generally prepared as an ester (see Schemes 2-4). Ester **1** (R is any suitable organic radical) is first hydrolyzed using base or, when the ester is a t-butyl group, using trifluoroacetic acid. The acid **2** is then coupled with the amino alcohol **3**. Depending on the nature of R¹ and R² an amino ketone may be used, in place of the amino alcohol, which avoids the subsequent oxidation step. In the case of fluoromethyl ketones where R¹ is CH₂F, the amino alcohol **3** may be obtained according to the method of Revesz et al., *Tetrahedron Lett.*, **1994**, 35, 9693. Finally the hydroxyl in compound **4** is oxidized and the compound treated appropriately according to the nature of R². For example, if the product **I** requires R² to be a carboxylic acid, then R² in **3** is preferably an ester and the final step in the scheme is hydrolysis (alternatively

-19-

if the ester is a tert-butyl ester, the final step is treatment with trifluoroacetic acid).

The parent tricyclic esters **1** may be prepared as outlined in Schemes II, III and IV for **1a**, **1b** and **1c** respectively, as shown below.

Scheme II



10 Details: (a) NaNO₂/HCl, NaN₃/AcONa; (b) SOCl₂, lithium anion of lactam **7**; (c) PPh₃/ xylene.


The tricyclic esters **1a** where X₂-X₁ is N=C, can be prepared as outlined in Scheme II. The starting aminoacid **5** is first converted into the diazonium salt, and then treated with sodium azide in aqueous sodium acetate to give the azidoacid **6**. The azidoacid **6** is then coupled to the lactam **7** by condensation of the acid chloride of **6** (prepared in situ from reaction of **6** with thionyl chloride), with the lithium salt of lactam **7** (prepared by reaction of LDA with **7**) to give **8**. Intramolecular aza-Wittig reaction of **8**, using triphenylphosphine and refluxing xylene, affords the tricyclic esters **1a**.

-20-

The tricyclic esters **1b**, where X_1 and X_2 are both carbon, can be prepared as outlined in Scheme III.

Scheme III


5



Details: (a) NBS, chloroform; (b) SOCl_2 , lithium anion of lactam **7**; (c) $\text{P}(\text{OEt})_3$; (d) LHMDS, THF.

10 The starting ortho substituted aromatic acid **9**
is first brominated (NBS in chloroform) to provide
bromide **10**. The acid chloride of **10** (prepared by reaction
of **10** with thionyl chloride) is then reacted with the
lithium salt of lactam **7** (prepared by reaction of LDA
15 with lactam **7**) to give **11**. Reaction of **11** with
triethylphosphite provides **12**, which undergoes an
intramolecular Wittig-Horner reaction in the presence of
a base in THF to afford tricyclic esters **1b**.

-21-

Scheme IV

Reagents: (a) diisopropylethylamine, toluene.

5 The tricyclic esters **1c**, where X_2-X_1 is $C(=O)-N$, can be prepared by reaction of heterocyclic esters of the type **13** with aromatic anhydrides **14**, as outlined in Scheme IV above.

10 The parent heterocyclic esters **7** and **13** used in Schemes II, III and IV, or their acids or derivatives, are either commercially available or can be prepared using standard methods. The parent heterocyclic acid **7**, where n is zero, is commercially available (pyroglutamic acid). In addition, pyroglutamic acid can be substituted
 15 at position 4 using various electrophiles, according to standard methods (J. Ezquerra et al., *Tetrahedron*, **1993**, 49, 8665-8678; J.D. Charrier et al., *Tetrahedron Lett.*, **1998**, 39, 2199-2202). The parent heterocyclic ester **7**, where n is one, can be prepared according to the
 20 procedures described in the experimental section below. The parent heterocyclic acid **7**, where n is two, can be prepared by standard methods (Perrotti et al., *Ann.Chim (Rome)*, **1966**, 56, 1368). The parent heterocyclic esters **13** where n is zero can be prepared by literature methods
 25 (M.R. Mish et al., *J.Am.Chem.Soc.*, **1997**, 119, 35, 8379-8380); and the parent heterocyclic esters **13** where n is one also can be prepared by literature methods (Y. Nakamura et al., *Chem. Lett.*, **1991**, 11, 1953-1956).

-22-

The compounds of this invention are designed to inhibit caspases. Therefore, the compounds of this invention can be assayed for their ability to inhibit apoptosis, the release of IL-1 β or caspase activity directly. Assays for each of the activities are known in the art and are described below in detail in the Testing section.

One embodiment of this invention relates to a composition comprising a compound of formula I or a pharmaceutically acceptable derivative thereof, and a pharmaceutically acceptable carrier.

If pharmaceutically acceptable salts of the compounds of this invention are utilized in these compositions, those salts are preferably derived from inorganic or organic acids and bases. Included among such acid salts are the following: acetate, adipate, alginate, aspartate, benzoate, benzene sulfonate, bisulfate, butyrate, citrate, camphorate, camphor sulfonate, cyclopentanepropionate, digluconate, dodecylsulfate, ethanesulfonate, fumarate, glucoheptanoate, glycerophosphate, hemisulfate, heptanoate, hexanoate, hydrochloride, hydrobromide, hydroiodide, 2-hydroxyethanesulfonate, lactate, maleate, methanesulfonate, 2-naphthalenesulfonate, nicotinate, oxalate, pamoate, pectinate, persulfate, 3-phenyl-propionate, picrate, pivalate, propionate, succinate, tartrate, thiocyanate, tosylate and undecanoate. Base salts include ammonium salts, alkali metal salts, such as sodium and potassium salts, alkaline earth metal salts, such as calcium and magnesium salts, salts with organic bases, such as dicyclohexylamine

-23-

salts, N-methyl-D-glucamine, and salts with amino acids such as arginine, lysine, and so forth.

Also, the basic nitrogen-containing groups can be quaternized with such agents as lower alkyl halides, such as methyl, ethyl, propyl, and butyl chloride, bromides and iodides; dialkyl sulfates, such as dimethyl, diethyl, dibutyl and diamyl sulfates, long chain halides such as decyl, lauryl, myristyl and stearyl chlorides, bromides and iodides, aralkyl halides, such as benzyl and phenethyl bromides and others. Water or oil-soluble or dispersible products are thereby obtained.

A "pharmaceutically acceptable derivative or prodrug" means any pharmaceutically acceptable salt, ester, salt of an ester or other derivative of a compound of this invention which, upon administration to a recipient, is capable of providing, either directly or indirectly, a compound of this invention or an inhibitorily active metabolite or residue thereof. Particularly favored derivatives or prodrugs are those that increase the bioavailability of the compounds of this invention when such compounds are administered to a patient (e.g., by allowing an orally administered compound to be more readily absorbed into the blood) or which enhance delivery of the parent compound to a biological compartment (e.g., the brain or lymphatic system) relative to the parent species.

Pharmaceutically acceptable prodrugs of the compounds of this invention include, without limitation, esters, amino acid esters, phosphate esters, metal salts and sulfonate esters.

Pharmaceutically acceptable carriers that may be used in these compositions include, but are not

-24-

limited to, ion exchangers, alumina, aluminum stearate, lecithin, serum proteins, such as human serum albumin, buffer substances such as phosphates, glycine, sorbic acid, potassium sorbate, partial glyceride mixtures of
5 saturated vegetable fatty acids, water, salts or electrolytes, such as protamine sulfate, disodium hydrogen phosphate, potassium hydrogen phosphate, sodium chloride, zinc salts, colloidal silica, magnesium trisilicate, polyvinyl pyrrolidone, cellulose-based
10 substances, polyethylene glycol, sodium carboxymethylcellulose, polyacrylates, waxes, polyethylene-polyoxypropylene-block polymers, polyethylene glycol and wool fat.

According to a preferred embodiment, the
15 compositions of this invention are formulated for pharmaceutical administration to a mammal, preferably a human being.

Such pharmaceutical compositions of the present invention may be administered orally, parenterally, by
20 inhalation spray, topically, rectally, nasally, buccally, vaginally or via an implanted reservoir. The term "parenteral" as used herein includes subcutaneous, intravenous, intramuscular, intra-articular, intra-synovial, intrasternal, intrathecal, intrahepatic,
25 intralesional and intracranial injection or infusion techniques. Preferably, the compositions are administered orally or intravenously.

Sterile injectable forms of the compositions of this invention may be aqueous or oleaginous suspension.
30 These suspensions may be formulated according to techniques known in the art using suitable dispersing or wetting agents and suspending agents. The sterile

-25-

injectable preparation may also be a sterile injectable solution or suspension in a non-toxic parenterally acceptable diluent or solvent, for example as a solution in 1,3-butanediol. Among the acceptable vehicles and solvents that may be employed are water, Ringer's solution and isotonic sodium chloride solution. In addition, sterile, fixed oils are conventionally employed as a solvent or suspending medium. For this purpose, any bland fixed oil may be employed including synthetic mono- or di-glycerides. Fatty acids, such as oleic acid and its glyceride derivatives are useful in the preparation of injectables, as are natural pharmaceutically-acceptable oils, such as olive oil or castor oil, especially in their polyoxyethylated versions. These oil solutions or suspensions may also contain a long-chain alcohol diluent or dispersant, such as carboxymethyl cellulose or similar dispersing agents which are commonly used in the formulation of pharmaceutically acceptable dosage forms including emulsions and suspensions. Other commonly used surfactants, such as Tweens, Spans and other emulsifying agents or bioavailability enhancers which are commonly used in the manufacture of pharmaceutically acceptable solid, liquid, or other dosage forms may also be used for the purposes of formulation.

The pharmaceutical compositions of this invention may be orally administered in any orally acceptable dosage form including, but not limited to, capsules, tablets, aqueous suspensions or solutions. In the case of tablets for oral use, carriers that are commonly used include lactose and corn starch. Lubricating agents, such as magnesium stearate, are also

-26-

typically added. For oral administration in a capsule form, useful diluents include lactose and dried cornstarch. When aqueous suspensions are required for oral use, the active ingredient is combined with
5 emulsifying and suspending agents. If desired, certain sweetening, flavoring or coloring agents may also be added.

Alternatively, the pharmaceutical compositions of this invention may be administered in the form of
10 suppositories for rectal administration. These can be prepared by mixing the agent with a suitable non-irritating excipient which is solid at room temperature but liquid at rectal temperature and therefore will melt in the rectum to release the drug.
15 Such materials include cocoa butter, beeswax and polyethylene glycols.

The pharmaceutical compositions of this invention may also be administered topically, especially when the target of treatment includes areas or organs
20 readily accessible by topical application, including diseases of the eye, the skin, or the lower intestinal tract. Suitable topical formulations are readily prepared for each of these areas or organs.

Topical application for the lower intestinal
25 tract can be effected in a rectal suppository formulation (see above) or in a suitable enema formulation. Topically-transdermal patches may also be used.

For topical applications, the pharmaceutical compositions may be formulated in a suitable ointment
30 containing the active component suspended or dissolved in one or more carriers. Carriers for topical administration of the compounds of this invention

-27-

include, but are not limited to, mineral oil, liquid petrolatum, white petrolatum, propylene glycol, polyoxyethylene, polyoxypropylene compound, emulsifying wax and water. Alternatively, the pharmaceutical compositions can be formulated in a suitable lotion or cream containing the active components suspended or dissolved in one or more pharmaceutically acceptable carriers. Suitable carriers include, but are not limited to, mineral oil, sorbitan monostearate, polysorbate 60, cetyl esters wax, cetearyl alcohol, 2-octyldodecanol, benzyl alcohol and water.

For ophthalmic use, the pharmaceutical compositions may be formulated as micronized suspensions in isotonic, pH adjusted sterile saline, or, preferably, as solutions in isotonic, pH adjusted sterile saline, either with or without a preservative such as benzylalkonium chloride. Alternatively, for ophthalmic uses, the pharmaceutical compositions may be formulated in an ointment such as petrolatum.

The pharmaceutical compositions of this invention may also be administered by nasal aerosol or inhalation. Such compositions are prepared according to techniques well known in the art of pharmaceutical formulation and may be prepared as solutions in saline, employing benzyl alcohol or other suitable preservatives, absorption promoters to enhance bioavailability, fluorocarbons, and/or other conventional solubilizing or dispersing agents.

The above-described compositions are particularly useful in therapeutic applications relating to an IL-1 mediated disease, apoptosis mediated disease, an inflammatory disease, autoimmune disease, destructive

-28-

bone disorder, proliferative disorder, infectious disease, degenerative disease, disease associated with cell death, excess dietary alcohol intake disease, and viral mediated disease. Such diseases include uveitis, inflammatory peritonitis, osteoarthritis, pancreatitis, asthma, adult respiratory distress syndrome, glomerulonephritis, rheumatoid arthritis, systemic lupus erythematosus, scleroderma, chronic thyroiditis, Grave's disease, autoimmune gastritis, diabetes, autoimmune hemolytic anemia, autoimmune neutropenia, thrombocytopenia, chronic active hepatitis, myasthenia gravis, inflammatory bowel disease, Crohn's disease, psoriasis, atopic dermatitis, scarring, graft vs host disease, organ transplant rejection, osteoporosis, leukemias and related disorders, myelodysplastic syndrome, multiple myeloma-related bone disorder, acute myelogenous leukemia, chronic myelogenous leukemia, metastatic melanoma, Kaposi's sarcoma, multiple myeloma, haemorrhagic shock, sepsis, septic shock, burns, Shigellosis, Alzheimer's disease, Parkinson's disease, Huntington's disease, Kennedy's disease, prion disease, cerebral ischemia, epilepsy, myocardial ischemia, acute and chronic heart disease, myocardial infarction, congestive heart failure, atherosclerosis, coronary artery bypass graft, spinal muscular atrophy, amyotrophic lateral sclerosis, multiple sclerosis, HIV-related encephalitis, aging, alopecia, neurological damage due to stroke, ulcerative colitis, traumatic brain injury, spinal cord injury, hepatitis-B, hepatitis-C, hepatitis-G, yellow fever, dengue fever, or Japanese encephalitis, various forms of liver disease, renal disease, polyaptic kidney disease, H. pylori-associated

-29-

gastric and duodenal ulcer disease, HIV infection, tuberculosis, and meningitis. The compounds and compositions are also useful in treating complications associated with coronary artery bypass grafts and as a component of immunotherapy for the treatment of various forms of cancer.

The amount of compound present in the above-described compositions should be sufficient to cause a detectable decrease in the severity of the disease or in caspase activity and/or cell apoptosis, as measured by any of the assays described in the examples.

The compounds of this invention are also useful in methods for preserving cells, such as may be needed for an organ transplant or for preserving blood products. Similar uses for caspase inhibitors have been reported (Schierle et al., Nature Medicine, 1999, 5, 97). The method involves treating the cells or tissue to be preserved with a solution comprising the caspase inhibitor. The amount of caspase inhibitor needed will depend on the effectiveness of the inhibitor for the given cell type and the length of time required to preserve the cells from apoptotic cell death.

According to another embodiment, the compositions of this invention may further comprise another therapeutic agent. Such agents include, but are not limited to, thrombolytic agents such as tissue plasminogen activator and streptokinase. When a second agent is used, the second agent may be administered either as a separate dosage form or as part of a single dosage form with the compounds or compositions of this invention.

-30-

It should also be understood that a specific dosage and treatment regimen for any particular patient will depend upon a variety of factors, including the activity of the specific compound employed, the age, body weight, general health, sex, diet, time of administration, rate of excretion, drug combination, and the judgment of the treating physician and the severity of the particular disease being treated. The amount of active ingredients will also depend upon the particular compound and other therapeutic agent, if present, in the composition.

In a preferred embodiment, the invention provides a method of treating a mammal, having one of the aforementioned diseases, comprising the step of administering to said mammal a pharmaceutically acceptable composition described above. In this embodiment, if the patient is also administered another therapeutic agent or caspase inhibitor, it may be delivered together with the compound of this invention in a single dosage form, or, as a separate dosage form. When administered as a separate dosage form, the other caspase inhibitor or agent may be administered prior to, at the same time as, or following administration of a pharmaceutically acceptable composition comprising a compound of this invention.

In order that this invention be more fully understood, the following preparative and testing examples are set forth. These examples are for the purpose of illustration only and are not to be construed as limiting the scope of the invention in any way.

-31-


Experimental

In the following Examples, ^{19}F NMR are ^1H decoupled and all peaks are singlets unless otherwise stated.

5

Example 1


[3S/R(1S)]-3-(2,3-Dihydro-1H-9-oxo-pyrrolo[2,1-b]quinazolin-1-carboxamido)-5-fluoro-4-oxo-pentanoic acid



10

Method A:

(S)-1-(2-Azido-benzoyl)-5-oxo-pyrrolidine-2-carboxylic acid tert-butyl ester



15

A stirred solution of (2S)-5-oxo-proline tert-butyl ester (T. Kolasa and M.J. Miller, J. Org. Chem., **1990**, 55, 1711-1721) (1.13g, 6.13mmol) in anhydrous THF (15mL) was treated at -78°C with LDA (9.19mmol) and the reaction was stirred for 15min. A solution of 2-azidobenzoyl chloride (T. Okawa, T. Sugimori, S. Eguchi and A. Kakehi, Heterocycles, **1998**, 47, 1, 375-382) (6.13mmol) in anhydrous THF (5mL) was then added dropwise and the reaction mixture was stirred at -78°C for 1h before being quenched with saturated aq. NH_4Cl . The reaction was

20


25

-32-

allowed to warm to room temperature and the organic layer was washed with saturated aq.NH₄Cl, dried (MgSO₄), filtered and evaporated to give an oil which was purified by flash chromatography (20% ethyl acetate in hexane) to afford the title compound as a pale yellow oil (1.67g, 82%): ¹H NMR (400MHz, CDCl₃) δ 1.53 (9H, s), 2.14 (1H, m), 2.43 (1H, m), 2.55 (1H, m), 2.69 (1H, m), 4.79 (1H, dd, *J* 9.2, 3.2Hz), 7.19–7.22 (2H, m), 7.36 (1H, m), 7.49 (1H, m). ¹³C NMR (100MHz, CDCl₃) δ 22.1 (CH₂), 28.3 (CH₃), 31.9 (CH₂), 59.3 (CH), 83.0 (C), 118.7 (CH), 125.0 (CH), 127.9 (C), 129.1 (CH), 131.9 (CH), 137.9 (C), 167.5 (C), 170.2 (C), 173.6 (C).

Method B:

(S)-2,3-Dihydro-1*H*-9-oxo-pyrrolo[2,1-*b*]quinazolin-1-carboxylic acid tert-butyl ester




Triphenylphosphine (1.19g, 4.54mmol) was added portionwise to a solution of (3*S*/*R*)-5-fluoro-4-oxo-3-[(*S*)-9-oxo-1,2,3,9-tetrahydro-pyrrolo[2,1-*b*]quinazoline-1-carbonyl)-amino]-pentanoic acid (1.36g, 4.12mmol) in xylene (60mL) at room temperature. The reaction mixture was stirred at room temperature until the evolution of nitrogen ceased (approx.1h), and then refluxed for 20h. The volatiles were evaporated and the residue was purified by flash chromatography (50% ethyl acetate in hexane) to afford the title compound as a colourless oil

-33-

(1.05g, 89%): ^1H NMR (400MHz, CDCl_3) δ 1.44 (9H, s), 2.26 (1H, m), 2.51 (1H, m), 3.06 (1H, m), 3.20 (1H, m), 4.99 (1H, dd, J 9.5, 2.8Hz), 7.39 (1H, m), 7.59 (1H, m), 7.68 (1H, m), 8.21 (1H, m). ^{13}C NMR (100MHz, CDCl_3) δ 24.6 (CH₂), 28.3 (CH₃), 31.5 (CH₂), 60.4 (CH), 83.3 (C), 120.9 (C), 126.7 (CH), 126.9 (CH), 127.2 (CH), 134.7 (CH), 149.5 (C), 159.4 (C), 160.8 (C), 169.3 (C).

Method C:

10 (S)-2,3-Dihydro-1H-9-oxo-pyrrolo[2,1-b]quinazolin-1-carboxylic acid




15 A solution of (1S)-9-oxo-1,2,3,9-tetrahydro-pyrrolo[2,1-b]quinazoline-1-carboxylic acid tert-butyl ester (1.01g, 3.53 mmol) in TFA (20mL) was stirred at room temperature for 4h. The mixture was concentrated under reduced pressure and the residue was dissolved in dry DCM. This process was repeated several times to remove excess TFA. The gum was triturated with diethyl ether, filtrated and washed several times with diethyl ether to afford the title compound as a white powder (620mg, 76%): ^1H NMR (400MHz, CD_3OD) δ 2.40 (1H, m), 2.71 (1H, m), 3.19 (1H, m), 3.27 (1H, m), 4.91 (exchangeable H), 5.19 (1H, dd, J 9.8, 2.8Hz), 7.53 (1H, m), 7.69 (1H, m), 7.85 (1H, m), 8.23 (1H, m).

-34-

Method D:

[3S/R, 4S/R, (1S)]-3-(2,3-Dihydro-1H-9-oxo-pyrrolo[2,1-b]quinazolin-1-carboxamido)-5-fluoro-4-hydroxy-pentanoic acid tert-butyl ester

5




A mixture of (S)-9-oxo-1,2,3,9-tetrahydro-pyrrolo[2,1-b]quinazoline-1-carboxylic acid (0.10g, 0.434mmol),
10 3-amino-5-fluoro-4-hydroxy-pentanoic acid tert-butyl ester (0.099g, 0.48mmol), HOBt (0.065g, 0.48mmol), and DMAP (0.058g, 0.48mmol) in anhydrous THF (7mL) was treated with EDC (0.092g, 0.48mmol) at 0°C with stirring. The reaction mixture was allowed to warm to room
15 temperature over 18h, after which it was concentrated under reduced pressure to give a gum. This was purified by flash chromatography (EtOAc) to afford the title compound as a white powder (155mg, 85%): ¹H NMR (400MHz, DMSO-d₆) δ 1.41 (9H, m), 1.99-3.07 (6H, m), 3.53-4.55 (4H, m), 4.91-5.12 (1H, m), 5.37-5.62 (1H, m), 7.42 (1H, m),
20 7.63 (1H, m), 7.80 (1H, m), 8.08 (1H, m), 8.29-8.57 (1H, m); ¹⁹F NMR (376MHz, DMSO-d₆) δ -226.5, -226.5, -226.7, -226.7, -227.9, -228.0, -229.0, -229.0.

25 Method E:

[3S/R, (1S)]-3-(2,3-Dihydro-1H-9-oxo-pyrrolo[2,1-b]quinazolin-1-carboxamido)-5-fluoro-4-oxo-pentanoic acid tert-butyl ester

-35-




A solution of [3S/R(1S)]-5-fluoro-4-hydroxy-3-(9-oxo-
5 1,2,3,9-tetrahydro-pyrrolo[2,1-b]quinazoline-1-
carboxamido)-pentanoic acid tert-butyl ester (0.147g,
0.35mmol) in anhydrous DCM (7mL) was treated with 1,1,1-
triaceotoxy-1,1-dihydro-1,2-benziodoxol-3(1H)-one (0.297g,
0.70mmol) with stirring at 0°C. The reaction mixture was
10 allowed to warm to room temperature and stirred for 18h
after which it was diluted with DCM and washed
sequentially with 10% aq. Na₂SO₃·5H₂O, saturated aq. NaHCO₃
and brine. The organic phase was dried (Na₂SO₄) and
concentrated to give a gum. This was purified by flash
15 chromatography (5% MeOH in DCM) to afford the title
compound as a white solid (113mg, 77%): ¹H NMR (400MHz,
CDCl₃) δ 1.35-1.42 (9H, 2s), 2.37-2.62 (2H, m), 2.76-2.82
(1H, m), 2.88-2.97 (1H, m), 3.05-3.12 (1H, m), 3.35-3.42
(1H, m), 4.85-5.30 (4H, m), 7.41-7.89 (4H, m), 8.19-8.23
20 (1H, m); ¹³C NMR (100MHz, CDCl₃) 24.1/24.2 (CH₂), 28.2/28.3
(CH₃), 32.0 (CH₂), 36.6 (CH₂), 52.8/52.9 (CH), 60.8/60.8
(CH), 82.7/82.7 (C), 84.7/84.8 (CH₂F), 120.0 (C), 126.8
(CH), 126.9/127.0 (CH), 127.4 (CH), 135.1 (CH),
149.4/149.5 (C), 159.5 (C), 161.5/161.6 (C), 169.4/169.7
25 (C), 170.2/170.3 (C), 202.6/202.8 (C); ¹⁹F NMR (376MHz,
CDCl₃) δ -231.9, -232.5.

-36-

Method F:

[3S/R(1S)]-3-(2,3-Dihydro-1H-9-oxo-pyrrolo[2,1-b]quinazolin-1-carboxamido)-5-fluoro-4-oxo-pentanoic acid



5


TFA (4mL) was added to a stirred ice cold solution of [3S/R(1S)]-5-fluoro-4-oxo-3-(9-oxo-1,2,3,9-tetrahydro-pyrrolo[2,1-b]quinazoline-1-carboxamido)-pentanoic acid tert-butyl ester (80mg, 0.19mmol) in anhydrous DCM (4mL). The mixture was stirred at 0°C for 0.5h then at room temperature for 0.5h. The mixture was concentrated under reduced pressure and then the residue was dissolved in dry DCM. This process was repeated several times in order to remove excess TFA. The gum was triturated with diethyl ether and the resulting solid collected by filtrated. The solid was washed several times with diethyl ether to afford the title compound as a white solid (65mg, 94%): IR (solid) 2366, 1793, 1675, 1557, 1194, 1137cm⁻¹; ¹H NMR (400MHz, DMSO-d₆) δ 2.04-2.13 (1H, m), 2.48-3.18 (5H, m), 4.33-5.42 (4H, m), 7.50 (1H, m), 7.64 (1H, m), 7.82 (1H, m), 8.10 (1H, m), 9.06-9.14 (1H, m), 12.61 (1H, br s); ¹³C NMR (100MHz, DMSO-d₆) δ 24.2/24.3 (CH₂), 31.0/31.1 (CH₂), 34.6/34.8 (CH₂), 52.1/52.6 (CH), 60.0/60.3 (CH), 84.3/84.4 (2xd, J 177.9, 177.7Hz, CH₂F), 120.47 (C), 126.2 (CH), 126.5 (CH), 127.0 (CH), 134.9 (CH), 149.3 (C), 149.3 (C), 160.1 (C), 160.7/160.8 (C), 170.6 (C), 172.1/172.2 (C), 202.4/202.7

-37-

(2xd, J 14.0, 14.0Hz, CO); ^{19}F NMR (376MHz, $\text{DMSO}-d_6$) δ -226.6 (t), -226.9 (t), -230.2 (t), -231.6 (t), -233.0 (t), -233.1 (t), -75.5 (s, TFA, 1 eq); MS (FAB +ve, HR) calculated for $\text{C}_{17}\text{H}_{17}\text{N}_3\text{O}_5\text{F}$ (MH $^+$) 362.115224, found 362.115448.

Example 2


[3S/R(9S)]-5-Fluoro-4-oxo-3-(11-oxo-6,7,8,9,-tetrahydro-11H-pyrido[2,1-b]quinazolin-9-carboxamido)-pentanoic acid



10

Method G:

(S)-Piperidine-1,2-dicarboxylic acid di-tert-butyl ester



15


To a solution of (S)-piperidine-2-carboxylic acid tert-butyl ester (M. Egbertson and S.J. Danishefsky, J. Org. Chem., **1989**, 54, 1, 11-12) (5.78g, 31.2mmol) in CH_3CN (30mL) at 0°C was added DMAP (763mg, 6.2mmol) followed by BOC_2O (10.22g, 46.8mmol). The reaction mixture was allowed to warm to room temperature and stirred for 20h. The solvents were evaporated under reduced pressure and the residue was purified by flash chromatography (10% ethyl acetate in hexane). The title compound was obtained as a colourless oil which crystallized upon standing (8.33g, 94%): ^1H NMR (400MHz, CDCl_3) δ 1.21-1.32

-38-

(2H, m), 1.47-1.48 (18H, 2s), 1.59-1.72 (3H, m), 2.18 (1H, m), 2.85-3.00 (1H, m), 3.89-4.01 (1H, 2d, J 11.9Hz), 4.47-4.58 (1H, 2br s).

5 Method H:


(S)-6-Oxo-piperidine-1,2-dicarboxylic acid di-tert-butyl ester



- 10 To a vigorously stirred solution of $\text{RuCl}_3 \cdot \text{H}_2\text{O}$ (2.39g, 11.5mmol) and NaIO_4 (24.6g, 115.0mmol) in water (250mL) was added (S)-piperidine-1,2-dicarboxylic acid di-tert-butyl ester (8.22g, 28.8mmol) in ethyl acetate (250mL) at room temperature. After stirring for 4h, the reaction
- 15 mixture was partitioned and the aqueous layer washed with ethyl acetate. To the combined organic layers was added $i\text{PrOH}$ (2.5mL) and stirring was continued for 2 hours in order to destroy excess RuO_4 . The precipitate was removed by filtration through a pad of celite and the filtrate
- 20 was evaporated under reduced pressure. The residue was purified by flash chromatography (30% ethyl acetate in hexane) to afford the title compound as a pale yellow oil, which crystallized upon standing (6.69g, 78%): ^1H NMR (400MHz, CDCl_3) δ 1.49 (9H, s), 1.52 (9H, s), 1.75-1.82
- 25 (2H, m), 1.97-2.06 (1H, m), 2.15-2.21 (1H, m), 2.41-2.61 (2H, m), 4.59 (1H, dd, J 3.5Hz)

-39-


Method I:

(S)-6-Oxo-piperidine-2-carboxylic acid tert-butyl ester

To a solution of (S)-6-oxo-piperidine-1,2-dicarboxylic
 5 acid di-tert-butyl ester (6.30g, 21.0mmol) in ethyl
 acetate (50mL) was added 1.1-M HCl in ethyl acetate
 (28.7mL, 31.5mmol). The reaction was stirred at room
 temperature for 1h, then washed with water, saturated
 aq. NaHCO₃ and brine. The organic phase was dried (MgSO₄),
 10 filtered and evaporated to afford the title compound as a
 yellow oil which crystallized upon standing (3.11g, 74%):
 1H NMR (400MHz, CDCl₃) δ 1.49 (9H, s), 1.74-1.94 (3H, m),
 2.18 (1H, m), 2.29-2.44 (2H, m), 3.95-3.98 (1H, m), 6.32
 (1H, br s); 13C NMR (100MHz, CDCl₃) δ 19.9 (CH₂), 25.9
 15 (CH₂), 28.4 (CH₃), 31.4 (CH₂), 55.7 (CH), 83.0 (C), 170.4
 (C), 171.9 (C).

[3S/R(9S)]-5-Fluoro-4-oxo-3-(11-oxo-6,7,8,9,-tetrahydro-
11H-pyrido[2,1-b]quinazolin-9-carboxamido)-pentanoic acid

20



This was prepared from (S)-6-oxo-piperidine-2-carboxylic
 acid tert-butyl ester using procedures similar to those
 described in methods A-F. The product was isolated as a
 25 white solid (139mg, 95%): IR (solid) 2361, 2342, 1727,
 1665, 1560, 1198, 1126cm⁻¹; ¹H NMR (400MHz, DMSO-d₆) □
 1.66-1.78 (2H, m), 2.14-2.17 (2H, m), 2.72 (2H, m), 2.92

-40-


(2H, m), 4.52-4.60 (1H, m), 4.80-5.30 (3H, m), 7.45-7.49 (1H, m), 7.58-7.60 (1H, m), 7.79-7.83 (1H, m), 8.06-8.09 (1H, m), 8.91 (1H, m), 12.51 (1H, br s); ^{13}C NMR (100MHz, DMSO- d_6) δ 16.6/16.7 (CH_2), 26.2/26.2 (CH_2), 31.7/31.8 (CH_2), 55.3/55.7 (CH), 120.2/120.2 (C), 126.4 (CH), 126.4 (CH), 126.4 (CH), 134.9 (CH), 147.5 (C), 155.2 (C), 161.8 (C), 171.2 (C); Signals for Asp moiety too broad to be detected in ^1H and ^{13}C NMR; ^{19}F NMR (376MHz, DMSO- d_6) \square - 233.0 (br).

10

Example 3

[3S/R(3S)]-3-(2,3-Dihydro-1H-5-oxo-pyrrolo[1,2-b]isoquinolin-3-carboxamido)-5-fluoro-4-oxo-pentanoic acid


15



Method J:

(S)-1-(2-Bromomethylbenzoyl)-5-oxo-pyrrolidine-2-carboxylic acid tert-butyl ester

20



A stirred solution of α -bromotoluic acid (L. Garuti, A. Ferranti, M. Roberti, E. Katz, R. Budriesi and A. Chiarini, Pharmazie, **1992**, 47, 295-297) (1.0g, 4.7mmol) in SOCl_2 (3.4mL) was heated at 80°C for 2h. The solvent was evaporated and the residue dissolved in toluene.


-41-

This process was repeated several times, to remove excess SOCl_2 , and to eventually afford the desired acid chloride as a yellow oil. A stirred solution of (2S)-5-oxo-proline tert-butyl ester (T. Kolasa, and M.J. Miller, J. Org. Chem., 1990, 55, 1711-1721) (861mg, 4.7mmol) in anhydrous THF (15mL) was treated at -78°C with LDA (7.0mmol) and the reaction was stirred for 15min. A solution of the 2- α -bromotoluoyl chloride, prepared above, in anhydrous THF (5mL) was then added dropwise and the reaction mixture was stirred at -78°C for 1h before being quenched with saturated aq. NH_4Cl . The reaction was allowed to warm to room temperature and partitioned. The organic layer was washed with saturated aq. NH_4Cl , dried (MgSO_4), filtered and evaporated to give an oil which was purified by flash chromatography (30% ethyl acetate in hexane) to afford the title compound as a pale yellow oil (1.46g, 82%): ^1H NMR (400MHz, CDCl_3) δ 1.55 (9H, s), 2.12-2.19 (1H, m), 2.38-2.59 (2H, m), 2.67-2.76 (1H, m), 4.54 (1H, d, J 10.5Hz), 4.70 (1H, d, J 10.5Hz), 4.86 (1H, dd, J 9.0, 3.7Hz), 7.36-7.50 (4H, m). ^{13}C NMR (100MHz, CDCl_3) \square 22.0 (CH_2), 28.4 (CH_3), 30.5 (CH_2), 32.0 (CH_2), 59.2 (CH), 83.2 (C), 128.3 (CH), 128.4 (CH), 131.0 (CH), 131.0 (CH), 135.2 (C), 135.5 (C), 169.6 (C), 170.4 (C), 173.6 (C).

25

Method K:

(S)-1-[2-(Diethoxyphosphorylmethyl)benzoyl]-5-oxo-pyrrolidine-2-carboxylic acid tert-butyl ester




-42-

A mixture of (S)-1-(2-bromomethyl-benzoyl)-5-oxo-pyrrolidine-2-carboxylic acid tert-butyl ester (898mg, 2.4mmol) and triethylphosphite (432mg, 2.4mmol) was heated at 70°C for 4h. After cooling, the residue was purified by flash chromatography (ethyl acetate) to afford the title compound as a clear viscous oil (872mg, 84%): ¹H NMR (400MHz, CDCl₃) δ 1.17 (3H, t, J 7.0Hz), 1.26 (3H, t, J 7.0Hz), 1.53 (9H, s), 2.07-2.14 (1H, m), 2.43-2.69 (3H, m), 3.12 (1H, dd, J 22.4, 15.0Hz), 3.62 (1H, dd, J 22.1, 15.0Hz), 3.84-4.06 (4H, m), 4.87 (1H, dd, J 8.9, 4.8Hz), 7.31-7.46 (4H, m).

Method L:

(S)-2,3-Dihydro-1H-5-oxo-pyrrolo[1,2-b]isoquinoline-3-carboxylic acid tert-butyl ester




To a solution of (S)-1-[2-(diethoxyphosphorylmethyl)-benzoyl]-5-oxo-pyrrolidine-2-carboxylic acid tert-butyl ester (865mg, 1.97mmol) in THF (15mL) at -40°C was added drop-wise 1.0-M LHMDS in THF (1.97mL, 1.97mmol). The reaction mixture was stirred at -40°C for 1h, allowed to warm to 0°C over 1h, stirred at 0°C for 1h and allowed to warm to 7°C over 30min before being quenched with saturated aq.NH₄Cl. The reaction mixture was extracted with ethyl acetate (x2). The combined organic layers were dried (MgSO₄), filtered and evaporated. The residue was purified by flash chromatography (20% ethyl acetate in hexane) to afford the title compound as a colourless

-43-

oil which crystallized upon standing (286mg, 51%): ^1H NMR (400MHz, CDCl_3) δ 1.47 (9H, s), 2.29 (1H, m), 2.47 (1H, m), 3.06 (1H, m), 3.19 (1H, m), 5.08 (1H, m), 6.42 (1H, s), 7.41-7.49 (2H, m), 7.63 (1H, m), 8.37 (1H, m); ^{13}C NMR (100MHz, CDCl_3) δ 25.8 (CH_2), 26.9 (CH_3), 28.7 (CH_2), 60.4 (CH), 81.3 (C), 99.3 (CH), 123.7 (C), 124.6 (CH_2), 126.5 (CH), 131.2 (CH), 137.3 (C), 142.4 (C), 160.2 (C), 168.7 (C).

10 [3S/R(3S)]-3-(2,3-Dihydro-1H-5-oxo-pyrrolo[1,2-b]isoquinolin-3-carboxamido)-5-fluoro-4-oxo-pentanoic acid



15 This was prepared from (S)-2,3-dihydro-(1H)-5-oxo-pyrrolo[1,2-b]isoquinoline-3-carboxylic acid tert-butyl ester using procedures similar to those described in methods C-F. The product was isolated as a white solid (102mg, 89%): IR (solid) 2356, 1742, 1655, 1588, 1209 cm^{-1} ;
20 ^1H NMR (400MHz, $\text{DMSO}-d_6$) δ 2.07-2.12 (1H, m), 2.40-2.93 (3H, m), 3.07-3.18 (2H, m), 4.34-5.45 (4H, m), 6.56-6.57 (1H, 2s), 7.41-7.45 (1H, m), 7.60-7.70 (2H, m), 8.11-8.16 (1H, m), 8.63-9.06 (1H, m), 12.49 (1H, br s); ^{13}C NMR (100MHz, $\text{DMSO}-d_6$) δ 26.7/26.8 (CH_2), 29.8/29.9 (CH_2),
25 34.6/34.9 (CH_2), 52.0/52.7 (CH), 61.4/61.7 (CH), 84.4/84.5 (2xd, J 177.7, 177.3Hz, CH_2F), 99.6/99.7 (CH), 124.4/124.4 (C), 125.8 (CH), 126.2 (CH), 126.9 (CH), 127.0 (CH), 138.6 (C), 145.4/145.4 (C), 160.6 (C), 171.1/171.2 (C),


-44-

172.1/172.2 (C), 202.4/202.9 (CO); ^{19}F NMR (376MHz, DMSO- d_6) δ -226.6 (t), -226.9 (t), -233.1 (t), -233.3 (t); MS (FAB +ve, HR) calculated for $\text{C}_{18}\text{H}_{17}\text{N}_2\text{O}_5\text{F}$ (MH+) 361.119975, found 361.120247.

5

Example 4

[3S/R(4S)]-5-Fluoro-4-oxo-3-(6-oxo-1,2,3,4-tetrahydro-6H-benzo[b]quinolizin-4-carboxamido)-pentanoic acid



10


This was prepared from (S)-6-oxo-piperidine-2-carboxylic acid tert-butyl ester using procedures similar to those described in methods J-L and C-F. The product was isolated as a white solid (108mg, 91%): IR (solid) 2361, 2337, 1736, 1641, 1365, 1217 cm^{-1} ; ^1H NMR (400MHz, DMSO- d_6) δ 1.66 (2H, m), 2.08-2.13 (2H, m), 2.53-2.94 (4H, m),, 4.29-4.69 (1H, m), 5.10-5.44 (3H, m), 6.43-6.46 (1H, m), 7.39-7.43 (1H, m), 7.54-7.56 (1H, m), 7.65-7.71 (1H, m), 8.09-8.14 (1H, m), 8.42-8.96 (1H, m, NH), 12.51 (1H, br s, OH); ^{13}C NMR (100MHz, DMSO- d_6) δ 16.7/16.8 (CH_2), 26.9/27.0 (CH_2), 28.9/29.0 (CH_2), 34.5/34.8 (CH_2), 52.1/52.8 (CH), 54.9/55.2 (CH), 84.3/84.5 (J 177.7, 177.1Hz, CH_2F), 103.8/103.8 (CH), 123.9 (C), 125.5 (CH), 125.8 (CH), 127.3 (CH), 132.9 (CH), 137.1 (C), 141.0/141.1 (C), 162.7 (C), 172.1/172.2 (C), 172.2/172.3 (C), 202.6/203.1 (J 14.6, 13.8Hz, CO); ^{19}F NMR (376MHz, DMSO- d_6) δ -226.6 (t), -226.9 (t), -233.2 (t), -233.4 (t).

-45-

Example 5


[3S/R(1S)]-3-(6,11-Dioxo-1,2,3,4-tetrahydro-
pyridazino[1,2-b]phthalazin-1-carboxamido)-5-fluoro-4-
oxo-pentanoic acid

5



Method M:

(S)-6,11-Dioxo-1,2,3,4-tetrahydro-pyridazino[1,2-
10 b]phthalazin-1-carboxylic acid methyl ester




A solution of (S)-hexahydro-pyridazine-3-carboxylic acid
15 methyl ester hydrochloride (Y. Nakamura, C.J Shin,
Chem.Lett, 1991, 11, 1953-1956) (370mg, 2.05mmol),
phthalic anhydride (318mg, 2.15mmol) and
diisopropylethylamine (291mg, 2.25mmol) was heated in
toluene (5mL) for 2h. The reaction mixture was then
20 cooled and partitioned between ethyl acetate and dilute
HCl. The organic phase was washed with saturated aq.
NaHCO₃, dried (MgSO₄), filtered and evaporated. The
residue was crystallised from hexane and filtered to
afford the title compound as a white solid (562mg, 82%):
25 ¹H NMR (400MHz, CD₃OD) δ 1.59 (1H, m), 1.96 (1H, m), 2.17
(1H, m), 2.55 (1H, m), 3.38 (1H, m), 3.70 (3H, s), 4.89

-46-

(1H, m), 5.74 (1H, m), 7.89 (2H, m), 8.16 (2H, m). ¹³C NMR (100MHz, CD₃OD) δ 21.2 (CH₂), 25.7 (CH₂), 46.0 (CH₂), 53.8 (CH), 58.1 (CH₃), 129.0 (CH), 129.1 (CH), 130.1 (C), 130.6 (C), 135.3 (CH), 135.7 (CH), 160.4 (C), 162.4 (C), 171.7 (C).

Method N:


(S)-6,11-Dioxo-1,2,3,4-tetrahydro-pyridazino[1,2-b]phthalazin-1-carboxylic acid



To a stirred solution of (S)-6,11-dioxo-1,2,3,4-tetrahydro-pyridazino[1,2-b]phthalazin-1-carboxylic acid methyl ester (1.078g, 3.93mmol) in MeOH (35mL) was added KOH (232mg, 4.12mmol) in MeOH (11mL) at 0°C. The reaction mixture was allowed to warm to room temperature and stirred for 20 hours, then concentrated under reduced pressure. The residue was dissolved in ethyl acetate and the resulting solution was extracted with water. The aqueous phase was acidified with 2.0-M HCl then extracted several times with ethyl acetate. The combined organic extracts were dried (MgSO₄), filtered and concentrated. The residue was crystallized from diethyl ether and the title compound was obtained as a white solid (744mg, 73%): ¹H NMR (400MHz, CD₃OD) δ 1.80 (1H, m), 1.97 (1H, m), 2.16 (1H, m), 2.56 (1H, m), 3.36 (1H, m), 4.83-4.88 (2H, m), 5.71 (1H, m), 7.90 (2H, m), 8.26 (2H, m).

-47-

[3S/R(1S)]-3-(6,11-Dioxo-1,2,3,4-tetrahydro-
pyridazino[1,2-b]phthalazin-1-carboxamido)-5-fluoro-4-
oxo-pentanoic acid



5

This was prepared from (S)-6,11-dioxo-1,2,3,4-tetrahydro-pyridazino[1,2-b]phthalazin-1-carboxylic acid using procedures similar to those described in methods D-F.


- 10 The product was isolated as a white solid (349mg, 85%):
IR (solid) 2356, 2337, 1736, 1651, 1617, 1603, 1346,
1226, 1212cm⁻¹; ¹H NMR (400MHz, DMSO-d₆) δ 1.62 (1H, m),
1.85 (1H, m), 2.11 (2H, m), 2.33 (1H, m), 2.70 (1H, m),
3.33 (1H, m), 4.54-4.96 (4H, m), 5.48 (1H, m), 7.87-7.94
15 (2H, m), 8.13-8.19 (2H, m), 8.72 (1H, m); ¹³C NMR (100MHz,
DMSO-d₆) (signals for Asp moiety not visible) δ 18.8 (2
peaks, CH₂), 24.9/24.1 (CH₂), 43.7 (CH₂), 56.7/56.8 (CH),
127.4/127.5 (CHar), 128.5 (2 peaks, Car), 129.2 (Car),
133.8/134.2 (CHar), 157.3 (CO), 159.4/159.6 (CO), 170.0
20 (CO); ¹⁹F NMR (376MHz, DMSO-d₆ + drop of TFA) δ -232.7,
-232.8; MS (FAB +ve, HR) calculated for C₁₈H₁₈N₃O₆F (MH+)
392.125789, found 392.125420.

-48-

Example 6

[3S/R(5S)]-(9,10-Dioxo-5,6,7,8,9,10-hexahydro-1,4,8a,10a-
tetraazaanthracene-5-carboxamido)-5-fluoro-4-oxo-3-

5 pentanoic acid



This was prepared from furo[3,4-b]pyrazine-5,7-
10 dione using procedures similar to those described in
methods M-N and D-F. The product was isolated as a white
solid (150mg, 90%): IR (solid) 1818, 1740, 1637, 1542,
1477, 1418, 1402, 1345, 1288, 1220, 1182, 1149, 1134,
1140, 1050, 934cm⁻¹; ¹H NMR (400MHz, DMSO-d₆) δ 1.57 (1H,
15 m), 1.85(1H, m), 2.10 (1H, m), 2.50-2.95 (2H, m, Asp CH₂),
3.49(1H, m), 4.22-4.72 (2.5H, m), 5.12 (1.5H, m); 5.46
and 5.55 (1H, 2xm), 8.85 (1H, m), 9.16 (2H, d); ¹³C NMR
(100MHz, DMSO-d₆) δ 18.8/19.1 (CH₂), 24.8/25.2 (CH₂),
32.9/33.1/34.5/34.6 (CH₂), 43.5/44.0/44.1 (Asp CH₂),
20 52.4/52.6 (CH), 57.3/57.4/57.6 (CH), 84.2/84.3 (J 178.5,
179.3Hz, CH₂F), 140.9/141.0 (C), 141.5 (C), 149.9 (CH),
150.0/150.1 (CH), 156.2/156.3/156.3 (C),
158.4/158.4/158.8 (C), 169.4/169.5/169.8/169.8 (C),
172.0/173.1 (C=O), 202.4/202.5 (J 14.6, 14.3Hz, C=O); ¹⁹F
25 NMR (376MHz, DMSO-d₆) δ -226.54(t), -227.1(t), -229.9(t),
-232.7(t), -232.8(t).

Example 7Enzyme Assays

The assays for caspase inhibition are based on the cleavage of a fluorogenic substrate by recombinant, purified human Caspases -1, -3, -7 or -8. The assays are run in essentially the same way as those reported by Garcia-Calvo et al. (J. Biol. Chem. 273 (1998), 32608-32613), using a substrate specific for each enzyme. The substrate for Caspase-1 is Acetyl-Tyr-Val-Ala-Asp-amino-4-methylcoumarin. The substrate for Caspases -3, -7 and -8 is Acetyl-Asp-Glu-Val-Asp-amino-4-methylcoumarin.

The observed rate of enzyme inactivation at a particular inhibitor concentration, k_{obs} , is computed by direct fits of the data to the equation derived by Thornberry et al. (Biochemistry 33 (1994), 3943-3939) using a nonlinear least-squares analysis computer program (PRISM 2.0; GraphPad software). To obtain the second order rate constant, k_{inact} , k_{obs} values are plotted against their respective inhibitor concentrations and k_{inact} values are subsequently calculated by computerized linear regression.

Table 3 below shows inhibition of caspase-1 activity for a selected compound of this invention as determined by the above method.

Table 3. Caspase-1 Activity

| Example Number | K_{inact} ($M^{-1}s^{-1}$) |
|----------------|--------------------------------|
| 2 | 455000 |

Table 4 below shows inhibition of caspase-3 activity for a selected compound of this invention as determined by the above method.

-50-

Table 4. Caspase-3 Activity

| Example Number | Kinact ($M^{-1}s^{-1}$) |
|----------------|---------------------------|
| 1 | 160500 |

Table 5 below shows inhibition of caspase-7 for a selected compound of this invention as determined by the above methods.

Table 5. Caspase-7 Activity

| Example Number | Kinact ($M^{-1}s^{-1}$) |
|----------------|---------------------------|
| 3 | 229000 |

Table 6 below shows inhibition of caspase-8 activity for a selected compound of this invention as determined by the above methods.

Table 6. Caspase-8 Activity

| Example Number | Caspase-8 Kinact ($M^{-1}s^{-1}$) |
|----------------|-------------------------------------|
| 5 | 82000 |

Example 8

Inhibition of IL-1 β secretion from Mixed Population of
 5 Peripheral Blood Mononuclear Cells (PBMC)

Processing of pre-IL-1 β by caspase-1 can be measured in cell culture using a variety of cell sources. Human PBMC obtained from healthy donors provides a mixed population of lymphocyte and mononuclear cells that
 10 produce a spectrum of interleukins and cytokines in response to many classes of physiological stimulators.

-51-

Experimental procedure

The test compound is dissolved in Dimethyl Sulphoxide (DMSO, Sigma #D-2650) to give a 100 mM stock solution. This is diluted in complete medium consisting of RPMI containing 10% heat inactivated FCS (Gibco BRL #10099-141), 2mM L-Glutamine (Sigma, #G-7513), 100U penicillin and 100 µg/ml streptomycin (Sigma #P-7539). The final concentration range of test compound is from 100 µM down to 6 nM over eight dilution steps. The highest concentration of test compound is equivalent to 0.1% DMSO in the assay.

Human PBMC are isolated from Buffy Coats obtained from the blood bank using centrifugation on Ficoll-Paque leukocyte separation medium (Amersham, #17-1440-02) and the cellular assay is performed in a sterile 96 well flat-bottomed plate (Nunc). Each well contains 100 µl of the cell suspension, 1×10^5 cells, 50 µl of compound dilutions and 50 µl of LPS (Sigma #L-3012) at 50 ng/ml final concentration. Controls consist of cells +/- LPS stimulation and a serial dilution of DMSO diluted in the same way as compound. The plates are incubated for 16-18h at 37°C in 5% CO₂ & 95% humidity atmosphere.

After 16-18 h the supernatants are harvested after centrifuging the plates at 100 x g at 18°C for 15 min and assayed for their IL-1β content. Measurement of mature IL-1β in the supernatant is performed using the Quantikine kits (R&D Systems) according to manufacturer's instructions. Mature IL-1β levels of about 600-1500 pg/ml are observed for PBMCs in positive control wells.

The inhibitory potency of the compounds can be represented by an IC₅₀ value, which is the concentration

-52-

of inhibitor at which 50% of the mature IL-1 β is detected in the supernatant as compared to the positive controls. Table 7 shows inhibition of IL-1 β secretion from peripheral blood mononuclear cells for selected compounds of this invention as determined by the above methods.

Table 7. Inhibition of IL-1 β secretion from PBMC

| Example Number | IC ₅₀ (nM) |
|----------------|-----------------------|
| 4 | 569 |

Example 9

Anti-Fas Induced Apoptosis Assay

5 Cellular apoptosis may be induced by the binding of Fas ligand (FasL) to its receptor, CD95 (Fas). CD95 is one of a family of related receptors, known as death receptors, which can trigger apoptosis in cells via activation of the caspase enzyme cascade. The process is
10 initiated by the binding of the adapter molecule FADD/MORT-1 to the cytoplasmic domain of the CD-95 receptor-ligand complex. Caspase-8 then binds FADD and becomes activated, initiating a cascade of events that involve the activation of downstream caspases and
15 subsequent cellular apoptosis. Apoptosis can also be induced in cells expressing CD95 eg the Jurkat E6.1 T cell lymphoma cell line, using an antibody, rather than FasL, to crosslink the cell surface CD95.

20 Anti-Fas-induced apoptosis is also triggered via the activation of caspase-8. This provides the basis of a cell based assay to screen compounds for inhibition of the caspase-8-mediated apoptotic pathway.

-53-

Experimental Procedure

Jurkat E6.1 cells are cultured in complete medium consisting of RPMI-1640 (Sigma No) + 10% foetal calf serum (Gibco BRL No.10099-141) + 2mM L-glutamine (Sigma No. G-7513). The cells are harvested in log phase of growth. 100ml Cells at $5-8 \times 10^5$ cells/ml are transferred to sterile 50ml Falcon centrifuge tubes and centrifuged for 5 minutes at 100xg at room temperature. The supernatant is removed and the combined cell pellets resuspended in 25ml of complete medium. The cells are counted and the density adjusted to 2×10^6 cells/ml with complete medium.

The test compound is dissolved in dimethyl sulphoxide (DMSO) (Sigma No. D-2650) to give a 100mM stock solution. This is diluted to 400 μ M in complete medium, then serially diluted in a 96-well plate prior to addition to the cell assay plate.

100 μ l of the cell suspension (2×10^6 cells) is added to each well of a sterile 96-well round-bottomed cluster plate (Costar No. 3790). 50 μ l of compound solution at the appropriate dilution and 50 μ l of anti-Fas antibody, clone CH-11 (Kamiya No.MC-060) at a final concentration of 10ng/ml, are added to the wells. Control wells are set up minus antibody and minus compound but with a serial dilution of DMSO as vehicle control. The plates are incubated for 16-18hrs at 37°C in 5% CO₂ and 95% humidity.

Apoptosis of the cells is measured by the quantitation of DNA fragmentation using a 'Cell Death Detection Assay' from Boehringer-Mannheim, No. 1544 675. After incubation for 16-18hrs the assay plates are centrifuged at 100xg at room temperature for 5 minutes.

-54-

150 μ l of the supernatant are removed and replaced by
150 μ l of fresh complete medium. The cells are then
harvested and 200 μ l of the lysis buffer supplied in the
assay kit are added to each well. The cells are
5 triturated to ensure complete lysis and incubated for 30
minutes at 4°C. The plates are then centrifuged at
1900xg for 10 minutes and the supernatants diluted 1:20
in the incubation buffer provided. 100 μ l of this
solution is then assayed exactly according to the
10 manufacturer's instructions supplied with the kit. OD_{405nm}
is measured 20 minutes after addition of the final
substrate in a SPECTRAmax Plus plate reader (Molecular
Devices). OD_{405nm} is plotted versus compound
concentration and the IC₅₀ values for the compounds are
15 calculated using the curve-fitting program SOFTmax Pro
(Molecular Devices) using the four parameter fit option.

Table 8 shows the results of the activity of
selected compounds of this invention in the FAS induced
apoptosis assay.

20

Table 8. Activity in FAS Induced Apoptosis Assay


| Example Number | IC ₅₀ (nM) |
|----------------|-----------------------|
| 6 | 168 |

While we have described a number of embodiments
of this invention, it is apparent that our basic examples
25 may be altered to provide other embodiments, which
utilize the compounds and methods of this invention.
Therefore, it will be appreciated that the scope of this
invention is to be defined by the appended claims rather
than by the specific embodiments, which have been
30 represented by way of example.

-55-

We claim:

1. A compound of formula I:



I

or a pharmaceutically acceptable derivative thereof,
wherein:

R^1 is hydrogen, CHN_2 , R, or $-CH_2Y$;

R is an aliphatic group, an aryl group, an aralkyl group,
a heterocyclic group, or a heterocyclalkyl group;

Y is an electronegative leaving group;

R^2 is CO_2H , CH_2CO_2H , or esters, amides or isosteres
thereof;

X_2-X_1 is $N(R^3)-C(R^3)$, $C(R^3)_2-C(R^3)$, $C(R^3)_2-N$, $N=C$, $C(R^3)=N$,
 $C(R^3)=C$, $C(=O)-N$, or $C(=O)-C(R^3)$;

each R^3 is independently selected from hydrogen or C_{1-6}
aliphatic,

Ring C is a fused aryl ring;

n is 0, 1 or 2; and

each methylene carbon in Ring A is optionally and
independently substituted by $=O$, or by one or more
halogen, C_{1-4} alkyl, or C_{1-4} alkoxy.

2. The compound of claim 1 having one or more of
the following features:

(a) R^1 is $-CH_2Y$ wherein Y is a halogen, OR, SR, or
 $-OC=O(R)$, wherein R is an aryl group or heterocyclic
group;

-56-

- (b) R^2 is CO_2H or esters, amides or isosteres thereof;
- (c) $\text{X}_2\text{-X}_1$ is $\text{N}=\text{C}$, $\text{C}(\text{R}^3)=\text{C}$, or $\text{C}(=\text{O})\text{-N}$;
- (d) Ring C is a fused five or six-membered aromatic ring having zero to two heteroatoms; and
- (e) n is 0 or 1.

3. The compound of claim 2 wherein:

- (a) R^1 is $-\text{CH}_2\text{Y}$ wherein Y is a halogen, OR, SR, or $-\text{OC}=\text{O}(\text{R})$, wherein R is an aryl group or heterocyclic group;
- (b) R^2 is CO_2H or esters, amides or isosteres thereof;
- (c) $\text{X}_2\text{-X}_1$ is $\text{N}=\text{C}$, $\text{C}(\text{R}^3)=\text{C}$, or $\text{C}(=\text{O})\text{-N}$;
- (d) Ring C is a fused five or six-membered aromatic ring having zero to two heteroatoms; and
- (e) n is 0 or 1.

4. The compound of claim 3 wherein R^1 is $-\text{CH}_2\text{Y}$ wherein Y is F; R^2 is CO_2H or an ester or amide thereof; $\text{X}_2\text{-X}_1$ is $\text{N}=\text{C}$, $\text{CH}=\text{C}$, or $\text{C}(=\text{O})\text{-N}$; Ring C is benzene ring; and n is 0 or 1.

5. The compound of claim 1, said compound selected from the compounds listed in Table 2.

6. A pharmaceutical composition comprising a compound as claimed in any of claims 1-5 and a pharmaceutically acceptable carrier.

7. A method for treating a condition or disease in mammals that is alleviated by treatment with a caspase

-57-

inhibitor, comprising administering to a mammal in need of such a treatment a therapeutically effective amount of a compound as claimed in any of claims 1-5.

8. A method for treating a disease or condition selected from an IL-1 mediated disease, an apoptosis mediated disease, an inflammatory disease, an autoimmune disease, a destructive bone disorder, a proliferative disorder, an infectious disease, a degenerative disease, excess dietary alcohol intake disease, a viral mediated disease, or a disease associated with cell death, comprising administering to a mammal in need of such a treatment a therapeutically effective amount of a compound as claimed in any of claims 1-5.

9. A method for treating a disease or condition selected from uveitis, inflammatory peritonitis, osteoarthritis, pancreatitis, asthma, adult respiratory distress syndrome, glomerulonephritis, rheumatoid arthritis, systemic lupus erythematosus, scleroderma, chronic thyroiditis, Grave's disease, autoimmune gastritis, diabetes, autoimmune hemolytic anemia, autoimmune neutropenia, thrombocytopenia, chronic active hepatitis, myasthenia gravis, inflammatory bowel disease, Crohn's disease, psoriasis, atopic dermatitis, scarring, graft vs host disease, organ transplant rejection, osteoporosis, leukemias and related disorders, myelodysplastic syndrome, multiple myeloma-related bone disorder, acute myelogenous leukemia, chronic myelogenous leukemia, metastatic melanoma, Kaposi's sarcoma, multiple myeloma, haemorrhagic shock, sepsis, septic shock, burns, Shigellosis, Alzheimer's disease, Parkinson's disease,

-58-

Huntington's disease, Kennedy's disease, prion disease, cerebral ischemia, epilepsy, myocardial ischemia, acute and chronic heart disease, myocardial infarction, congestive heart failure, atherosclerosis, coronary artery bypass graft, spinal muscular atrophy, amyotrophic lateral sclerosis, multiple sclerosis, HIV-related encephalitis, aging, alopecia, neurological damage due to stroke, ulcerative colitis, traumatic brain injury, spinal cord injury, hepatitis-B, hepatitis-C, hepatitis-G, yellow fever, dengue fever, or Japanese encephalitis, various forms of liver disease, renal disease, polyaptic kidney disease, H. pylori-associated gastric and duodenal ulcer disease, HIV infection, tuberculosis, meningitis, a treatment for complications associated with coronary artery bypass grafts, or an immunotherapy for the treatment of various forms of cancer, comprising administering to a mammal in need of such a treatment a therapeutically effective amount of a compound as claimed in any of claims 1-5.

10. A method of treating complications associated with coronary artery bypass grafts, comprising administering to a mammal in need of such a treatment a therapeutically effective amount of a compound as claimed in any of claims 1-5.

11. A method of preserving cells, said method comprising the step of bathing the cells in a solution of a compound as claimed in any of claims 1-5.

12. A method of preserving an organ for organ transplant or for preserving a blood product, comprising

-59-

the step of bathing the organ or blood product in a solution of a compound as claimed in any of claims 1-5..

13. A method of immunotherapy for the treatment of cancer, comprising administering to a mammal in need of such a treatment a therapeutically effective amount of a compound as claimed in any of claims 1-5.

INTERNATIONAL SEARCH REPORT

International Application No.
PCT/US 01/18243

A. CLASSIFICATION OF SUBJECT MATTER

IPC 7 C07D487/04 C07D471/04 C07D487/22 A61K31/47 A61K31/50
A61K31/505 //(C07D487/04,239:00,209:00),(C07D471/04,221:00,
209:00)

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 C07D A61K A61P

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

EPO-Internal, WPI Data, PAJ, BIOSIS, CHEM ABS Data

C. DOCUMENTS CONSIDERED TO BE RELEVANT

| Category * | Citation of document, with indication, where appropriate, of the relevant passages | Relevant to claim No. |
|------------|--|-----------------------|
| Y | WO 95 35308 A (VERTEX PHARMA) 28 December 1995 (1995-12-28) abstract; claims 49,54,58,67-70,80 | 1-13 |
| Y | WO 95 33751 A (SANOFI WINTHROP INC) 14 December 1995 (1995-12-14) abstract; claims | 1-13 |
| A | WO 98 11109 A (IDUN PHARMACEUTICALS INC) 19 March 1998 (1998-03-19) abstract; claims | 1-13 |

☐ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

* Special categories of cited documents:

A document defining the general state of the art which is not considered to be of particular relevance

E earlier document but published on or after the international filing date

L document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

O document referring to an oral disclosure, use, exhibition or other means

P document published prior to the international filing date but later than the priority date claimed

T later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

X document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

Y document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art

G document member of the same patent family

Date of the actual completion of the international search

18 September 2001

Date of mailing of the international search report

25/09/2001

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax: (+31-70) 340-3016

Authorized officer

Frelon, D

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/US 01/18243

| Patent document cited in search report | | Publication date | Patent family member(s) | Publication date |
|---|---|---------------------|----------------------------|---------------------|
| WO 9535308 | A | 28-12-1995 | US 5756466 A | 26-05-1998 |
| | | | US 5656627 A | 12-08-1997 |
| | | | US 5847135 A | 08-12-1998 |
| | | | AP 797 A | 07-01-2000 |
| | | | AU 709114 B2 | 19-08-1999 |
| | | | AU 2944695 A | 15-01-1996 |
| | | | BG 101130 A | 29-08-1997 |
| | | | BR 9508051 A | 21-10-1997 |
| | | | CA 2192089 A1 | 28-12-1995 |
| | | | CN 1159196 A | 10-09-1997 |
| | | | CZ 9603698 A3 | 11-06-1997 |
| | | | EP 0784628 A1 | 23-07-1997 |
| | | | FI 965036 A | 14-02-1997 |
| | | | HU 76622 A2 | 28-10-1997 |
| | | | JP 10504285 T | 28-04-1998 |
| | | | NO 965365 A | 17-02-1997 |
| | | | NZ 289560 A | 29-09-1999 |
| | | | PL 318220 A1 | 26-05-1997 |
| | | | SK 160996 A3 | 10-09-1997 |
| | | | WO 9535308 A1 | 28-12-1995 |
| | | | US 6025147 A | 15-02-2000 |
| | | | US 5716929 A | 10-02-1998 |
| | | | US 6103711 A | 15-08-2000 |
| | | | US 5973111 A | 26-10-1999 |
| | | | ZA 9504988 A | 17-12-1996 |
| WO 9533751 | A | 14-12-1995 | US 5552400 A | 03-09-1996 |
| | | | AU 705882 B2 | 03-06-1999 |
| | | | AU 2769995 A | 04-01-1996 |
| | | | EP 0764167 A1 | 26-03-1997 |
| | | | HU 76334 A2 | 28-08-1997 |
| | | | JP 10501244 T | 03-02-1998 |
| | | | WO 9533751 A1 | 14-12-1995 |
| | | | US 5639745 A | 17-06-1997 |
| WO 9811109 | A | 19-03-1998 | AU 4413897 A | 02-04-1998 |
| | | | AU 4481997 A | 02-04-1998 |
| | | | AU 4583597 A | 02-04-1998 |
| | | | CA 2237314 A1 | 19-03-1998 |
| | | | CN 1234038 A | 03-11-1999 |
| | | | EP 0920444 A1 | 09-06-1999 |
| | | | EP 0929311 A1 | 21-07-1999 |
| | | | EP 0874850 A1 | 04-11-1998 |
| | | | JP 2001500377 T | 16-01-2001 |
| | | | JP 2000501428 T | 08-02-2000 |
| | | | JP 2001501923 T | 13-02-2001 |
| | | | WO 9811109 A1 | 19-03-1998 |
| | | | WO 9811129 A1 | 19-03-1998 |
| | | | WO 9810778 A1 | 19-03-1998 |
| | | | US 6200969 B1 | 13-03-2001 |
| | | | US 6187771 B1 | 13-02-2001 |
| | | | US 5968927 A | 19-10-1999 |

**This Page is Inserted by IFW Indexing and Scanning
Operations and is not part of the Official Record**

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- ☐ BLACK BORDERS
- ☐ IMAGE CUT OFF AT TOP, BOTTOM OR SIDES
- ☐ FADED TEXT OR DRAWING
- ☐ BLURRED OR ILLEGIBLE TEXT OR DRAWING
- ☐ SKEWED/SLANTED IMAGES
- ☐ COLOR OR BLACK AND WHITE PHOTOGRAPHS
- ☐ GRAY SCALE DOCUMENTS
- ☒ LINES OR MARKS ON ORIGINAL DOCUMENT
- ☐ REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY
- ☐ OTHER: _____

IMAGES ARE BEST AVAILABLE COPY.

As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.